- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19
- Interventions
- Bemnifosbuvir (BEM), Placebo
- Drug
- Lead sponsor
- Atea Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 61
- States / cities
- Kingman, Arizona • Prescott, Arizona • Surprise, Arizona + 46 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 1,115
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 707 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Duarte, California • Fullerton, California + 32 more
- Conditions
- Radiographic Axial Spondyloarthritis
- Interventions
- Tulisokibart, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 37
- States / cities
- Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 33 more
- Conditions
- COVID-19
- Interventions
- nirmatrelvir, ritonavir, placebo for nirmatrelvir
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 436 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 67
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Surprise, Arizona + 47 more
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Disease
- Interventions
- Donanemab, Aducanumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 31
- States / cities
- Fullerton, California • Irvine, California • Sherman Oaks, California + 27 more
- Conditions
- Arthralgia, Breast Cancer, Hot Flashes, Musculoskeletal Complications, Sexual Dysfunction
- Interventions
- testosterone, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 528
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Auburn, California + 331 more
- Conditions
- Alzheimer Disease
- Interventions
- Gantenerumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 67
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 58 more
- Conditions
- Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Cisplatin, Laboratory Biomarker Analysis, Placebo Administration, Veliparib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 798
- States / cities
- Anchorage, Alaska • Fort Smith, Arkansas • Hot Springs, Arkansas + 542 more
- Conditions
- Cutaneous Lupus Erythematosus
- Interventions
- Lanraplenib, Filgotinib, Lanraplenib placebo, Filgotinib placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 13
- States / cities
- Beverly Hills, California • Fullerton, California • Los Angeles, California + 10 more
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Metastatic Non-Cutaneous Melanoma, Non-Cutaneous Melanoma, Recurrent Cutaneous Melanoma, Recurrent Mucosal Melanoma, Recurrent Non-Cutaneous Melanoma
- Interventions
- Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b
- Procedure · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 552
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 379 more
- Conditions
- Asthma Patients
- Interventions
- AZD1981, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 19
- States / cities
- Fullerton, California • Los Angeles, California • Mission Viejo, California + 16 more
- Conditions
- Moderate-to-Severe Asthma
- Interventions
- Anti-GM-CSF Monoclonal Antibody 400mg, Placebo
- Biological · Other
- Lead sponsor
- Humanigen, Inc.
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Fullerton, California • Granada Hills, California + 27 more
- Conditions
- Breast Cancer
- Interventions
- Amcenestrant-matching placebo, SAR439859, Palbociclib, Letrozole, Goserelin, Letrozole-matching placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,068 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 45
- States / cities
- Daphne, Alabama • Glendale, Arizona • Tucson, Arizona + 40 more
- Conditions
- Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IB Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage II Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage III Pleural Diffuse Malignant Mesothelioma AJCC v7
- Interventions
- Atezolizumab, Cisplatin, Extrapleural Pneumonectomy, Pemetrexed Disodium, Pleurectomy, Radiation Therapy
- Drug · Procedure · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 174
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 121 more
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
- Interventions
- Spectris™ AD - Active, Spectris™ AD - Sham
- Device
- Lead sponsor
- Cognito Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 673 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 68
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more
- Conditions
- Colorectal Cancer
- Interventions
- celecoxib, 5-fluorouracil, placebo, oxaliplatin, leucovorin
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,527 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 826
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 536 more
- Conditions
- Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7
- Interventions
- Capecitabine, Fluorouracil, Intensity-Modulated Radiation Therapy, Leucovorin, Oxaliplatin, Pembrolizumab, Veliparib
- Drug · Radiation · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 645
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 449 more
- Conditions
- Geographic Atrophy
- Interventions
- APL-2, Sham Procedure
- Drug · Other
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 637 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 67
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 56 more
- Conditions
- Alzheimer's Disease
- Interventions
- Idalopirdine 60 mg
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 56 more
- Conditions
- Breast Cancer
- Interventions
- Entinostat, Atezolizumab, Placebo
- Drug
- Lead sponsor
- Syndax Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Bakersfield, California • Fullerton, California + 15 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- liraglutide, glimepiride, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 746 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 102
- States / cities
- Concord, California • Escondido, California • Fullerton, California + 83 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Fenebrutinib, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Fullerton, California • Las Vegas, Nevada
- Conditions
- Alzheimer's Disease
- Interventions
- KarXT, KarX-EC, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 586 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 31
- States / cities
- Fullerton, California • Irvine, California • Los Angeles, California + 28 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- GW642444 6.25, GW642444 3mcg, GW642444 12.5mcg, GW642444 25mcg, GW642444 50mcg, placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 49
- States / cities
- Florence, Alabama • Jasper, Alabama • Montgomery, Alabama + 45 more